Good morning :)
Switch to
Place Order

Hikal Ltd

HIKAL
Health CarePharmaceuticals
SmallcapWith a market cap of ₹4,396 cr, stock is ranked 557
Moderate RiskStock is 2.71x as volatile as Nifty
343.403.69% (-13.15)
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹4,396 cr, stock is ranked 557
Moderate RiskStock is 2.71x as volatile as Nifty

Key Metrics

PE RatioPE RatioPB RatioPB RatioDividend YieldDiv. Yield
27.394.120.45%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
35.924.360.88%

Forecast & RatingsDetailed Forecast 

33%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Hikal Limited is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma, ingredients, and contract research activities. The Company’s operating segments include the crop protection and pharmaceuticals space. The Crop protection produce and trades in pesticides and herbicides. Its facilities are in Taloja, Mahad (Maharashtra), and Panoli (Gujarat). The Pharmaceuticals space produce and trades in active pharmaceuticals ingredients. Its facilities are in Jigani (Bengaluru) and Panoli (Gujarat). The Company’s products and services include gabapentin, thiabendazole, and diuron contract development and custom manufacturing of intermediates, application programming interface (APIs), and artificial intelligence (AI’s). It offers solutions to route scouting, process development, analytical method development, technology development, process engineering, scale-up support, and small-scale synthesis.

Investor PresentationView older 

Nov 9, 2022

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

2019202020212022+1.59+1.51+1.73+1.95+0.10+0.08+0.13+0.16
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Related Party Transaction 
Announced OnNov 18, 2022

Hikal Limited has informed the Exchange about related party transaction for the half year ended September 30, 2022 | Download

Hikal Limited has informed the Exchange about related party transaction for the half year ended September 30, 2022 | Download

General updates 
Announced OnNov 16, 2022

Hikal Limited has informed the Exchange about Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Update | Download

Hikal Limited has informed the Exchange about Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Update | Download

Cash Dividend 
Ex. DateSep 14, 2022

Final • Div/Share: ₹ 0.4

See all events